Correspondence 0001493152-23-015584 from Imunon, Inc. (IMNN)
Imunon, Inc.
Date: May 5, 2023 · CIK: 0000749647 · Accession: 0001493152-23-015584
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-15911
Referenced dates: May 3, 2023
Letter
Imunon, Inc.
Lenox Drive, Suite 100
Lawrenceville, NJ 08648
May 5, 2023
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, N.E.
Washington, D.C. 20549
Attention: Vanessa Robertson/Kevin Vaughn
Re: Imunon, Inc.
Form 10-K for the fiscal year ended December 31, 2022
Filed March 30, 2023
File No. 001-15911
Ladies and Gentlemen:
This letter sets forth responses of Imunon, Inc. (the “Company” or “we”) to the comments of the staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) set forth in your letter dated May 3, 2023, with respect to the Form 10-K for the fiscal year ended December 31, 2022 filed with the Commission on March 30, 2023 (the “Form 10-K”).
The text of the Staff’s comments have been included in this letter for your convenience, and the Company’s responses to the comments have been provided immediately thereafter.
Form 10-K for the fiscal year ended December 31, 2022
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Results of Operations
Research and Development Expenses, page 60
1. Staff’s comment: Please revise your future filings to break out the development costs incurred during each period presented related to IMNN-001 and PLACCINE separately. If you do not track your research and development costs by program or platform, please disclose that fact and explain why you do not maintain and evaluate research and development costs by project or program. For amounts that are not tracked by project or program, provide other quantitative or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e. by nature or type of expense) which should reconcile to total research and development expense on the Statements of Operations.
Response:
The Company acknowledges the Staff’s comment. In its SEC filings, commencing with the Form 10-Q for the quarterly period ended March 31, 2023, the Company will separately break out the development costs related to IMNN-001 and PLACCINE incurred during each period presented.
We hope that the foregoing has been responsive to the Staff’s comments. If you have any questions related to this letter, please contact me at 1 (609) 896-9100.
Sincerely,
/s/
Jeffrey W. Church
Show Raw Text
CORRESP
1
filename1.htm
Imunon,
Inc.
997
Lenox Drive, Suite 100
Lawrenceville,
NJ 08648
May
5, 2023
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Vanessa Robertson/Kevin Vaughn
Re:
Imunon,
Inc.
Form
10-K for the fiscal year ended December 31, 2022
Filed
March 30, 2023
File
No. 001-15911
Ladies
and Gentlemen:
This
letter sets forth responses of Imunon, Inc. (the “Company” or “we”) to the comments of the staff of the Division
of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) set forth
in your letter dated May 3, 2023, with respect to the Form 10-K for the fiscal year ended December 31, 2022 filed with the Commission
on March 30, 2023 (the “Form 10-K”).
The
text of the Staff’s comments have been included in this letter for your convenience, and the Company’s responses to the comments
have been provided immediately thereafter.
Form
10-K for the fiscal year ended December 31, 2022
Management’s
Discussion and Analysis of Financial Condition and Results of Operations
Results
of Operations
Research
and Development Expenses, page 60
1.
Staff’s
comment: Please revise your future filings to break out the development costs incurred during each period presented related
to IMNN-001 and PLACCINE separately. If you do not track your research and development costs by program or platform, please disclose
that fact and explain why you do not maintain and evaluate research and development costs by project or program. For amounts that
are not tracked by project or program, provide other quantitative or qualitative disclosure that provides more transparency as to
the type of research and development expenses incurred (i.e. by nature or type of expense) which should reconcile to total research
and development expense on the Statements of Operations.
Response:
The
Company acknowledges the Staff’s comment. In its SEC filings, commencing with the Form 10-Q for the quarterly period ended March
31, 2023, the Company will separately break out the development costs related to IMNN-001 and PLACCINE incurred during each period presented.
1
We
hope that the foregoing has been responsive to the Staff’s comments. If you have any questions related to this letter, please contact
me at 1 (609) 896-9100.
Sincerely,
/s/
Jeffrey W. Church
Jeffrey
W. Church
Executive
Vice President and Chief Financial Officer
Via
E-mail:
cc:
Steven
Canner
Baker
& McKenzie LLP
2